LYZZ Capital is a global healthcare-dedicated venture capital and private equity firm based in Shanghai, China. The firm invests in talents, assets, and technologies with an emphasis on unmet medical needs and large market potential in China, managing over USD$600 million across USD and RMB funds.
67% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (47% of deals). Average disclosed round size is $75.2M (across 10 rounds with reported amounts).
Portfolio
10
Fund Size
$600M
Top Stage
Series A
Last 12 Mo
0
Team
KL
Kevin Li
Managing Partner
EZ
Eric Zhang
Partner
XC
Xiakai Cheng
Principal
ZY
Zhu Yong
Principal
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
15 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Wugen | Series B | $115M | Aug 2025 |
| Wugen | Series A | $115M | Jan 2025 |
 Mojia Biotech | Series A | $14.9M | Jan 2022 |
| Mojia Biotech | Series B | $80M | Jan 2022 |
 Neurelis, Inc. | Series D | $114M | Mar 2021 |
 Jumpcode Genomics | Series B | $21M | Jan 2021 |
| Wugen | Series B | $172M | Jan 2021 |
 Onchilles Pharma | Series A | $7M | Jan 2021 |
| MMabworks Biotech | Series C | — | Apr 2020 |
 Qpex Biopharma | Series A | $33M | Oct 2018 |
 Minova Pharma | Series A | — | — |
| 迈迈诺威医药 | Series A | — | — |
| 摩摩珈生物 | Series B | $80M | — |
| MMabworks Biotech | Series B | — | — |
| MMabworks Biotech | Series A | — | — |
Top Co-Investors
Bits x Bites3 shared
RiverVest Venture Partners3 shared
Abingworth LLP3 shared
Alpha Wave Incubation3 shared
Tybourne Capital Management3 shared
Oriza2 shared
Adams Street Partners1 shared
New Enterprise Associates1 shared
Scale Venture Partners1 shared
Terra Venture Partners1 shared
Decent Capital1 shared
Cormorant Asset Management1 shared
Decheng Capital1 shared
OrbiMed1 shared
HBM Healthcare Investments1 shared
IDG Capital1 shared
Lake Bleu Capital1 shared
Baird1 shared
Last updated: 7 October 2026